Alexion Pharmaceuticals Inc.
http://www.alexion.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alexion Pharmaceuticals Inc.
Metagenomi Looks For Upside To Moderna’s Exit
Moderna has cut short its alliance with Metagenomi, giving it more work to do in persuading skeptical investors about its gene-editing platform.
Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge
The weak yen helped push up both global revenues and costs for major Japanese firms in the fiscal year ended 31 March, while good mainstay growth benefited Daiichi Sankyo and Astellas. Chugai meanwhile had a challenging start to its calendar financial year due to lower pandemic drug stockpiling.
Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways
BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.
Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs
C-suite leaders from Lilly, Roche and J&J spoke at a Citeline-sponsored panel at Swiss Biotech Day in Basel and offered encouragement to start-ups trying to negotiate the tricky financial landscape.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- AstraZeneca PLC
- AstraZeneca Rare Disease
- Enobia Pharma Corp.
- LogicBio Therapeutics, Inc.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice